Skip to main content

Table 1 Comparisons of treatment compared to PBS only on circulating IgG, IgM, IL-1β and IL-6 levels

From: Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer

Timepoint

Comparison

Mean difference

95% CI of diff.

Significance

IgG

 Week 1

PBS v PEI/pDNA

10.40

4.20 to 16.61

**

PBS v RALA/pDNA

10.54

4.33 to 16.75

**

 Week 2

PBS v PEI/pDNA

− 0.02

− 6.23 to 6.20

ns

PBS v RALA/pDNA

0.03

− 6.18 to 6.24

ns

 Week 3

PBS v PEI/pDNA

− 13.89

− 20.1 to − 7.68

***

PBS v RALA/pDNA

− 5.07

− 11.28 to 1.15

ns

IgM

 Week 1

PBS v PEI/pDNA

2.66

− 23.05 to 28.37

ns

PBS v RALA/pDNA

− 2.18

− 27.89 to 23.52

ns

 Week 2

PBS v PEI/pDNA

− 10.44

− 36.15 to 15.27

ns

PBS v RALA/pDNA

− 11.99

− 37.7 to 13.72

ns

 Week 3

PBS v PEI/pDNA

− 30.79

− 56.5 to − 5.08

*

PBS v RALA/pDNA

− 20.98

− 46.69 to 4.73

ns

Il-1β

 Week 1

PBS v PEI/pDNA

4.20

− 3.29 to 11.69

ns

PBS v RALA/pDNA

6.77

− 0.72 to 14.26

ns

 Week 2

PBS v PEI/pDNA

− 1.94

− 9.43 to 5.55

ns

PBS v RALA/pDNA

4.19

− 3.31 to 11.68

ns

 Week 3

PBS v PEI/pDNA

− 4.73

− 12.22 to 2.76

ns

PBS v RALA/pDNA

− 3.27

− 10.76 to 4.22

ns

IL6

 Week 1

PBS v PEI/pDNA

− 27.61

− 52.87 to − 2.35

*

PBS v RALA/pDNA

− 26.24

− 51.50 to 0.97

*

 Week 2

PBS v PEI/pDNA

10.61

− 14.66 to 35.87

ns

PBS v RALA/pDNA

− 2.41

− 27.67 to 22.85

ns

 Week 3

PBS v PEI/pDNA

17.74

− 7.52 to 43.00

ns

PBS v RALA/pDNA

2.80

− 22.47 to 28.06

ns

  1. *p < 0.05; **p < 0.01; ***p < 0.001